Sanofi

Why Investors Shouldn't Worry About Sanofi's Poor Quarter

Why Investors Shouldn't Worry About Sanofi's Poor Quarter

Motley Fool

Athersys Has Some Promise, But Controversy And Doubt Remain

Athersys Has Some Promise, But Controversy And Doubt Remain

Seeking Alpha

Regeneron acquires full rights to two novel development programs from Sanofi

Regeneron acquires full rights to two novel development programs from Sanofi

Yahoo/Fly on the Wall

Sanofi 1Q net drops 45 percent as generic competition slashes sales of Plavix, other drugs

Sanofi 1Q net drops 45 percent as generic competition slashes sales of Plavix, other drugs

Yahoo/AP

Sanofi distances itself from consultant caught up in tax fraud probe

Sanofi distances itself from consultant caught up in tax fraud probe

Fierce Pharma

In Moribund Cholesterol Field, A New Drug Emerges

In Moribund Cholesterol Field, A New Drug Emerges

Forbes

4 Stocks Pushing The Drugs Industry Downward

4 Stocks Pushing The Drugs Industry Downward

TheStreet.com

Sanofi's Vaccine Gets EU Approval

Sanofi's Vaccine Gets EU Approval

Yahoo/Zacks

Lilly And Sanofi CEOs Take Two Very Different R&D Paths In Alzheimer's Disease

Lilly And Sanofi CEOs Take Two Very Different R&D Paths In Alzheimer's Disease

Forbes

Why Did Vanda Pharmaceuticals Hit A 52-Week High?

Why Did Vanda Pharmaceuticals Hit A 52-Week High?

Seeking Alpha